Daniel Ives is CEO and founder of Shift Bioscience, a preclinical drug discovery and
development company developing the first small molecule drug for safe repair of
mitochondria, the energy producing organelle. Daniel was a mitochondrial researcher for 7
years (2009-2016), based first at the MRC Mitochondrial Biology Unit and later at the Crick
Institute. Daniel discovered small molecules that restore mitochondrial function by reducing
the level of pathogenic mitochondrial genomes. The technology provides a powerful
approach (pun intended) to combating ageing, diseases of ageing and mitochondrial orphan
diseases. Daniel gained his PhD from the University of Cambridge.